Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?

被引：0

作者：

Orlando, Laura ^{[1
,2
]}

Cinieri, Saverio ^{[1
,2
]}

机构：

[1] Antonio Perrino Hosp, Med Oncol Div, Brindisi, Italy

[2] Antonio Perrino Hosp, Breast Unit, Brindisi, Italy

来源：

FUTURE ONCOLOGY | 2017年 / 13卷 / 16期

关键词：

endocrine-positive breast cancer; endocrine resistance; EVEROLIMUS PLUS EXEMESTANE; FULVESTRANT; 500; MG; GROWTH-FACTOR; PALBOCICLIB; INHIBITOR; LETROZOLE;

D O I：

10.2217/fon-2017-0101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1361 / 1364

页数：4

共 20 条

[1]

[Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043

[2] Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E [J].

Butt, AJ ;

McNeil, CM ;

Musgrove, EA ;

Sutherland, RL .

[3] ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J].

Cardoso, F. ;

Costa, A. ;

Norton, L. ;

Senkus, E. ;

Aapro, M. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Blackwell, K. L. ;

Cardoso, M. J. ;

Cufer, T. ;

El Saghir, N. ;

Fallowfield, L. ;

Fenech, D. ;

Francis, P. ;

Gelmon, K. ;

Giordano, S. H. ;

Gligorov, J. ;

Goldhirsch, A. ;

Harbeck, N. ;

Houssami, N. ;

Hudis, C. ;

Kaufman, B. ;

Krop, I. ;

Kyriakides, S. ;

Lin, U. N. ;

Mayer, M. ;

Merjaver, S. D. ;

Nordstrom, E. B. ;

Pagani, O. ;

Partridge, A. ;

Penault-Llorca, F. ;

Piccart, M. J. ;

Rugo, H. ;

Sledge, G. ;

Thomssen, C. ;

van't Veer, L. ;

Vorobiof, D. ;

Vrieling, C. ;

West, N. ;

Xu, B. ;

Winer, E. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :1871-1888

[4] Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition [J].

Dean, Jeffry L. ;

McClendon, A. Kathleen ;

Knudsen, Erik S. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (34) :29075-29087

[5] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer [J].

Di Leo, Angelo ;

Jerusalem, Guy ;

Petruzelka, Lubos ;

Torres, Roberto ;

Bondarenko, Igor N. ;

Khasanov, Rustem ;

Verhoeven, Didier ;

Pedrini, Jose L. ;

Smirnova, Iya ;

Lichinitser, Mikhail R. ;

Pendergrass, Kelly ;

Garnett, Sally ;

Lindemann, Justin P. O. ;

Sapunar, Francisco ;

Martin, Miguel .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4594-4600

[6] Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). [J].

Dickler, Maura N. ;

Barry, William Thomas ;

Cirrincione, Constance T. ;

Ellis, Matthew James ;

Moynahan, Mary Ellen ;

Innocenti, Federico ;

Hurria, Arti ;

Rugo, Hope S. ;

Lake, Diana ;

Hahn, Olwen Mary ;

Schneider, Bryan P. ;

Tripathy, Debu ;

Winer, Eric P. ;

Hudis, Clifford A. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[7] Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J].

Dowsett, M. ;

Forbes, J. F. ;

Bradley, R. ;

Ingle, J. ;

Aihara, T. ;

Bliss, J. ;

Boccardo, F. ;

Coates, A. ;

Coombes, R. C. ;

Cuzick, J. ;

Dubsky, P. ;

Gnant, M. ;

Kaufmann, M. ;

Kilburn, L. ;

Perrone, F. ;

Rea, D. ;

Thuerlimann, B. ;

van de Velde, C. ;

Pan, H. ;

Peto, R. ;

Davies, C. ;

Gray, R. ;

Baum, M. ;

Buzdar, A. ;

Sestak, I. ;

Markopoulos, C. ;

Fesl, C. ;

Jakesz, R. ;

Colleoni, M. ;

Gelber, R. ;

Regan, M. ;

von Minckwitz, G. ;

Snowdon, C. ;

Goss, P. ;

Pritchard, K. ;

Anderson, S. ;

Costantino, J. ;

Mamounas, E. ;

Ohashi, Y. ;

Watanabe, T. ;

Bastiaannet, E. .

LANCET, 2015, 386 (10001) :1341-1352

[8] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

[9] The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].

Finn, Richard S. ;

Crown, John P. ;

Lang, Istvan ;

Boer, Katalin ;

Bondarenko, Igor M. ;

Kulyk, Sergey O. ;

Ettl, Johannes ;

Patel, Ravindranath ;

Pinter, Tamas ;

Schmidt, Marcus ;

Shparyk, Yaroslav ;

Thummala, Anu R. ;

Voytko, Nataliya L. ;

Fowst, Camilla ;

Huang, Xin ;

Kim, Sindy T. ;

Randolph, Sophia ;

Slamon, Dennis J. .

LANCET ONCOLOGY, 2015, 16 (01) :25-35

[10] Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance [J].

Garcia-Becerra, Rocio ;

Santos, Nancy ;

Diaz, Lorenza ;

Camacho, Javier .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (01) :108-145

← 1 2 →